Overview
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
CLL/SLL Expert Insights
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL.
January 19, 2023: Zanubrutinib received FDA approval for CLL/SLL.
January 27, 2023: Pirtobrutinib received FDA approval for mantle cell lymphoma.
December 1, 2023: Pirtobrutinib received accelerated FDA approval for CLL/SLL.
• Discuss the limitations that are typically associated with currently available targeted agents used for the management of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
• Evaluate the most up-to-date clinical trial data surrounding emerging Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of CLL/SLL in the relapsed/refractory setting
• Apply recent evidence of emerging BTK inhibitors into the clinical context of current paradigms in the area of CLL/SLL
| Chair | |
 | Nitin Jain, MD Associate Professor Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, TX |
| Co-Chair | |
 | Jacqueline Barrientos, MD, MS Chief, Hematologic Malignancies Director, Oncology Research Assistant Professor Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Adjunct Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell Adjunct Associate Professor, Feinstein Institutes for Medical Research Mount Sinai Medical Center Miami Beach, FL |
| Faculty | |
 | Catherine Coombs, MD Associate Clinical Professor Division of Hematology/Oncology Department of Medicine UCI Health Orange, CA |
 | Sameer Parikh, MD, MBBS Assistant Professor of Medicine Department of Medicine Division of Hematology Mayo Clinic Rochester, MN |
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair(s), planning committee member, faculty/teacher/author, or CME activity reviewer relationships with an ineligible company that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all financial relationships with any ineligible company. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: pirtobrutinib and nemtabrutinib for CLL/SLL.
| Faculty | Commercial Interest |
| Nitin Jain, MD* | Consulting fee: AbbVie Inc., Adaptive Biosciences, AstraZeneca US, Beigene, Bristol-Myers Squibb Company, CareDx, Cellectis, Genentech, Inc., Ipsen US, Janssen Biotech, Inc., Pharmacyclics LLC, MEI Pharma, Precision Biosciences, Servier Pharmaceuticals, TG Therapeutics Honoraria: Janssen Biotech, Inc., MEI Pharma, Novartis Pharmaceutical Corporation, TG Therapeutics |
| Jacqueline Barrientos, MD, MS* | Advisor: AstraZeneca US, Beigene, MEI Pharma, Pharmacyclics LLC Grant or research support: Oncternal, Pharmacyclics LLC, Velosbio |
| Catherine Coombs, MD* | Consulting fee: AbbVie Inc., AstraZeneca US, Beigene, Genentech, Inc., Lilly USA, LLC, Honoraria: Janssen Biotech, Inc., MEI Pharma, MingSight, Novartis Pharmaceuticals Corporation, TG Therapeutics Membership on advisory committees or review panel: Octapharma Speakers bureau: AbbVie Inc., Genentech, Inc. |
| Sameer Parikh, MD, MBBS* | Advisor: AbbVIe Inc., Amgen Inc., AstraZeneca US, Janssen Biotech, Inc., Merck Sharp & Dohme Corp., Novalgen Limited, Pharmacyclics LLC, TG Therapeutics Grant or research support: AstraZeneca US, Genentech, Inc., Janssen Biotech, Inc., Merck Sharp & Dohme Corp. |
Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below.
The following financial relationships have been provided:
| Planning Committee Members | Commercial Interest |
| Nitin Jain, MD | Consulting fee: AbbVie Inc., Adaptive Biosciences, AstraZeneca US, Beigene, Bristol-Myers Squibb Company, CareDx, Cellectis, Genentech, Inc., Ipsen US, Janssen Biotech, Inc., Pharmacyclics LLC, MEI Pharma, Precision Biosciences, Servier Pharmaceuticals, TG Therapeutics Honoraria: Janssen Biotech, Inc., MEI Pharma, Novartis Pharmaceuticals Corporation, TG Therapeutics |
| Jacqueline Barrientos, MD, MS | Advisor: AstraZeneca US, Beigene, MEI Pharma, Pharmacyclics LLC Grant or research support: Oncternal, Pharmacyclics LLC, Velosbio |
Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers below have indicated NO financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity.
| Planning Committee Members | ||
| Aminah Abdullah Emily Bennett Katlyn Cooper Michelle Forcier, MS | Danya Garner, PhD, MSN, RN Tamara Greiner, MA, CHCP Don Hallagan Lisa Keckich Ritesh Kothari | Natasha Mitchner, PhD Laurie Novoryta Anne Perch, MBA, CHCP Vanessa Senatore Margaret Sheils |
| CME Activity Reviewers/Approver |
| Samuel Kareff, MD, MPH |
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
